PIQUR Therapeutics ’ PQR309 granted EMA Orphan Drug Designation for DLBCL

Swiss clinical-stage pharmaceutical company PIQUR Therapeutics has received orphan drug designation from the European Medicines Agency (EMA) for its lead compound, PQR309, indicated to be used on patients with diffuse large B-cell lymphoma (DLBCL).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news